pf-04958242
Small moleculeexperimental
Clinical trial activity
16 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
14
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2010 (NCT01159483)
Timeline
Indications
Mechanism of action
- Glutamate receptor ionotropic AMPAPOSITIVE ALLOSTERIC MODULATOR
Glutamate receptor ionotropic AMPA positive allosteric modulator
Binds to LBD (ligand binding domain) of GRIA2.
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3707379 ↗
Also known as
- pf-04958242
- pf-04958242
- pf-04958242
- pf-04958242
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05148481 | Phase 1 | Nov 23, 2021 | Biogen |
| NCT04079101 | Phase 1 | Oct 2, 2019 | Biogen |
| NCT04068532 | Phase 1 | Oct 2, 2019 | Biogen |
| NCT03745820 | Phase 2 | Nov 15, 2018 | Biogen |
| NCT02855411 | Phase 2 | Aug 1, 2016 | Pfizer |
| NCT02341482 | Phase 1 | Feb 1, 2015 | Pfizer |
| NCT02332798 | Phase 1 | Jan 1, 2015 | Pfizer |
| NCT02228395 | Phase 1 | Sep 1, 2014 | Pfizer |
| NCT01749098 | Phase 1 | Dec 1, 2012 | Pfizer |
| NCT01646840 | Phase 1 | Jul 1, 2012 | Pfizer |
| NCT01518920 | Phase 1 | Dec 1, 2011 | Pfizer |
| NCT01518894 | Phase 1 | Nov 1, 2011 | Pfizer |
| NCT01365338 | Phase 1 | Jun 1, 2011 | Pfizer, Yale University |
| NCT01511510 | Phase 1 | Jun 1, 2011 | Pfizer |
| NCT01238679 | Phase 1 | Nov 1, 2010 | Pfizer |
| NCT01159483 | Phase 1 | Aug 1, 2010 | Pfizer |
Showing 16 of 16 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 12 | 12 | 2 | 2010 |
| Biogen | For profit | 4 | 4 | 2 | 2018 |
| Yale University | Academic/Hospital | 1 | 0 | 1 | 2011 |
3 organizations
Page 1 / 1